Navigation Links
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Date:5/20/2009

BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding planned publications of results from clinical trials with blinatumomab and adecatumumab, the efficacy, safety and intended utilization of our pro
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015  Kerastem Technologies announce that the Company ... FDA Center For Biologics Evaluation and Research (CBER) Office ... clinical trial investigating the safety and feasibility of the ... male pattern baldness (androgenic alopecia). The phase ... clinical work in Europe and ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
(Date:7/27/2015)... July 27, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Thursday, July 30, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn of viscose ... the EU. For instance, it surpassed the EUR 106 million mark (in value terms) ... Germany is a major producer, while Italy is a key consumer. , The ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... Optimizing transfection conditions using LipoTAXI transfection reagent ... Systems , Soverin Karmiol ,Clonetics Corporation, Walkersville, ... novel liposome reagent that offers,low cellular toxicity ... cells. A procedure is described for optimizing ...
... pcmv-script PCR cloning kit , , Tanya Hosfield ... Cloning Systems, Inc. , , Stratagene has expanded the ... a new vector for high-efficiency cloning of PCR,fragments and ... kit uses a PCR cloning method ...
... LipoTAXI transfection reagent: A proven choice ... , LipoTAXI transfection ... and cells growing in,suspension. In this article, we ... effectiveness of LipoTAXI reagent. Optimizing transfection,conditions is a ...
Cached Biology Technology:Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 2Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 4Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 5Mammalian Expression Vector for Efficient Cloning of PCR Fragments 2Mammalian Expression Vector for Efficient Cloning of PCR Fragments 3Mammalian Expression Vector for Efficient Cloning of PCR Fragments 4Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 2Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 3Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 4Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 6Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 7
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... for energy, but too much sugar can create ... unwanted structural changes. Standard methods to monitor glucose ... cell culture. A team of engineers at the ... Microelectronics is developing an alternative approach that takes ...
... of European experts on biodiversity will gather from the 21th ... further improve the transfer of biodiversity knowledge from the scientific ... take part in a project funded by the European Commission: ... researchers and practitioners to help all actors in the field ...
... milk powder and in meat-based baby food, residues of ... University of Almera (Spain) have developed a system to ... as tilmicosine, or antiparasitic drugs, such as levamisole, are ... they can remain later in food. Scientists from the ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2A new method detects traces of veterinary drugs in baby food 2
...
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
Biology Products: